BioCentury | Jul 2, 2020
Product Development

First Phase III data for an IL-6 mAb in COVID-19 disappoint

A Phase III miss for IL-6 inhibitor Kevzara may not reflect a broader problem with the target or the strengthening theory that immune modulators are the best line of defense against severe forms of COVID-19....
BioCentury | Jun 27, 2020
Product Development

A mechanistic view of four compounds that disrupt interleukin pathways to treat severe COVID-19

Master protocols for COVID-19 clinical trials are testing half a dozen molecules that aim to prevent respiratory distress in patients with severe disease by targeting the host immune system -- four of these compounds intervene...
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

Breaking through the noise of poor-quality clinical studies are the first clear signals of a treatment paradigm for COVID-19, indicating how and when to use the two major therapeutic approaches -- attacking the virus and...
BioCentury | Jun 6, 2020
Product Development

Over 200 COVID-19 trials nearing completion should provide a busy summer of data readouts

Less than three months after COVID-19 reached pandemic status, and five since the virus was sequenced, drug development has reached the point where hundreds of clinical trials will soon read out. With a pile of...
BioCentury | May 27, 2020
Deals

Sanofi's sale of Regeneron stake for $11B could set stage for both companies' growth through M&A

More than 16 years and five product launches after closing its first deal with Regeneron, Sanofi has sold its holding of roughly 20% of the biotech's shares for about $11.1 billion. While the French pharma...
BioCentury | Apr 28, 2020
Product Development

Actemra anti-IL-6 data in COVID-19 outshines Regeneron’s Kevzara readout

Regeneron shed $2.1 billion in market cap Monday after an IDMC recommended amendments that would narrow the scope of its Phase III trial of Kevzara sarilumab in advanced COVID-19 patients. Also likely weighing on the...
BioCentury | Apr 1, 2020
Product Development

The Race Is On: Strategies for COVID-19 Product Development

Industry leaders and policy advisers on the front lines of the fight against COVID-19 in the U.S. and China joined BioCentury on March 31 for a webinar about the race to develop medical countermeasures. The...
BioCentury | Mar 28, 2020
Deals

Sanofi adds to COVID-19 pipeline with Translate deal

A partnership with Translate Bio to develop an mRNA-based vaccine is one of multiple shots on goal Sanofi is preparing against COVID-19. The collaboration is part of a 2018 deal in which Sanofi (Euronext:SAN; NASDAQ:SNY)...
BioCentury | Mar 26, 2020
Politics, Policy & Law

Revamped Senate stimulus bill would provide $27B to HHS to combat pandemic

The U.S. Senate’s latest COVID-19 stimulus bill would appropriate $340 billion to support local and national agencies to combat the pandemic, including billions for biopharma R&D. HHS’s Public Health and Social Services Emergency Fund would...
BioCentury | Mar 24, 2020
Product Development

Biopharma execs highlight regulatory collaboration, call for increased manufacturing, data sharing

Executives at biopharmas developing vaccines and therapeutics to treat COVID-19 provided updates on clinical timelines, the positive impact of regulatory collaboration and the need to dramatically expand manufacturing capacity in order to respond more quickly...
Items per page:
1 - 10 of 87